Davis Polk advised the representatives of the underwriters in the offering. Stoke Therapeutics, Inc. completed the $112 million public offering of 2,500,000 shares of common stock,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now